Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ-Reference-Cited by-同舟云学术

Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ

Published:2014-03-10 Issue:1 Volume:33 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Pahl Jens HW,Kwappenberg Kitty MC,Varypataki Eleni M,Santos Susy J,Kuijjer Marieke L,Mohamed Susan,Wijnen Juul T,van Tol Maarten JD,Cleton-Jansen Anne-Marie,Egeler R Maarten,Jiskoot Wim,Lankester Arjan C,Schilham Marco W

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1186/1756-9966-33-27.pdf

Reference54 articles.

1. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 2008, 26: 633-638. 10.1200/JCO.2008.14.0095.

2. Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 2014, 33: 12-10.1186/1756-9966-33-12.

3. Yang J, Zhang W: New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013, 25: 398-406. 10.1097/CCO.0b013e3283622c1b.

4. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PCW, Lankester AC, Cleton-Jansen AM: Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011, 17: 2110-2119. 10.1158/1078-0432.CCR-10-2047.

5. Nathan CF, Murray HW, Cohn ZA: The macrophage as an effector cell. N Engl J Med. 1980, 303: 622-626. 10.1056/NEJM198009113031106.

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer;Scientific Reports;2024-08-02

2. Identification of drug-like molecules targeting the ATPase activity of dynamin-like EHD4;PLOS ONE;2024-07-29

3. NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy;Frontiers in Immunology;2024-06-11

4. Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies;Frontiers in Cell and Developmental Biology;2024-06-10

5. Identification of drug-like molecules targeting the ATPase activity of dynamin-like EHD4;2024-04-11